Method for large scale production of recombinant DNA-derived...

Details Method for large scale production of recombinant DNA-derived... Method for large scale production of recombinant DNA-derived...

2005-10-18

2005-10-18

Nashed, Nashaat T. (Department: 1652)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C435S091100, C435S320100, C536S023100, C536S023200

Reexamination Certificate

active

06955910

ABSTRACT:
The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant therof or a (Kringle 2 Serine) K2S molecule or a variant therof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.

REFERENCES:
patent: 5840533 (1998-11-01), Niwa et al.
patent: 6027888 (2000-02-01), Georgiou et al.
patent: 6083715 (2000-07-01), Georgiou et al.
patent: 2003/0013150 (2003-01-01), Manosroi et al.
patent: 2003/0049729 (2003-03-01), Manosroi et al.
patent: 0 302 456 (1989-02-01), None
patent: 0 357 391 (1990-03-01), None
patent: 0 467 676 (1992-01-01), None
patent: 1 048 732 (2000-11-01), None
patent: 1 077 263 (2001-02-01), None
patent: WO 97/38123 (1997-10-01), None
patent: WO 98/54199 (1998-12-01), None
patent: WO 02/40650 (2002-05-01), None
patent: WO 02/40696 (2002-05-01), None
Hu, S.Z., et al., “Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts,”Cancer Res. 56:3055-3061, American Association for Cancer Research (1996).
Huston, J.S., et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA 85:5879-5883, National Academy of Sciences (1988).
Kortt, A.A., et al., “Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer,”Protein Eng. 10:423-433, Oxford University Press (1997).
Lovejoy, B., et al., “Crystal Structure of a Synthetic Triple-Stranded α-Helical Bundle,”Science 259:1288-1293, American Association for the Advancement of Science (1993).
NCBI Entrez, Genbank report, Accession No. AF268281, from Rader, C., and Barbas, C. F. III (Oct. 2000).
Pack, P., et al., “Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation ofEscherichia coli,” Bio/Technology 11:1271-1277, Nature Publishing Co. (1993).
Pack, P., et al., “Tetravalent Miniantibodies with High Avidity Assembling inEscherichia coli,” J. Mol. Biol. 246:28-34, Academic Press Ltd. (1995).
Perisic, O., et al., “Crystal structure of a diabody, a bivalent antibody fragment,”Structure 2:1217-1226, Current Biology Ltd. (1994).
Sivaprasadarao, A. and Findlay, J.B., “Expression of functional human-retinol-binding protein inEscherichia coliusing a secretion vector,”Biochem. J. 296:209-215, Biochemical Society/Portland Press (1993).
NCBI Entrez, GenBank Report, Accession No. E02814, from Habuka, N., et al. (1991).
Barbas, C.F. III and J. Wagner, “Synthetic Human Antibodies: Selecting and Evolving Functional Proteins,”Methods 8:94-103, Academic Press (1995).
Bennett, W.F. et al., “High Resolution Analysis of Functional Determinants on Human Tissue-type Plasminogen Activator,”J. Biol. Chem. 266:5191-5201, The American Society for Biochemistry and Molecular Biology, Inc. (1991).
Betton, J.-M. et al., “Degradation versus Aggregation of Misfolded Maltose-binding Protein in the Periplasm ofEscherichia coli,” J. Biol. Chem. 273:8897-8902, The American Society for Biochemistry and Molecular Biology, Inc. (1998).
Allen, S. et al., “Intracellular Folding of Tissue-type Plasminogen Activator. Effects of Disulfide Bond Formation on N-linked Glycosylation and Secretion,”J. Biol. Chem. 270:4797-4804, The American Society for Biochemistry and Molecular Biology, Inc. (1995).
Ames, G.F.-L. et al., “Simple, Rapid, and Quantitative Release of Periplasmic Proteins by Chloroform,”J. Bacteriol. 160:1181-1183, American Society for Microbiology (1984).
Barbas, C.F. III et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,”Proc. Natl. Acad. Sci. U.S.A. 88:7978-7982, The National Academy of Sciences of the U.S.A. (1991).
Camiolo, S.M. et al., “Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin and Plasmin,”Proc. Soc. Exp. Biol. Med. 138:277-280, Academic Press (1971).
Cartwright, T., “Production of tPA from Animal Cell Cultures,” InAnimal Cell Biotechnology,vol. 5, R.E. Spier and J.B. Griffiths (eds.), Academic Press, N.Y. p. 217-245 (1992).
Curry, K.A. et al., “Escherichia coliExpression and Processing of Human Interleukin-1β Fused to Signal Peptides,”DNA Cell Biol. 9:167-175, Mary Ann Liebert, Inc. (1990).
Datar, R.V. et al., “Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator,”Bio/Technology 11:349-357, Nature Publishing Company (1993).
Denèfle, P. et al., “Heterologous protein export inEscherichia coli:influence of bacterial signal peptides on the export of human interleukin 1β,”Gene 85:499-510, Elsevier Science Publishers B.V. (Biomedical Division) (1989).
Griffiths, J.B. and A. Electricwala, “Production of Tissue Plasminogen Activators from Animal Cells,”Adv. Biochem. Eng. Biotechnol. 34:147-166, Springer-Verlag (1987).
Harris, T.J.R. et al., “Cloning of cDNA Coding for Human Tissue-type Plasminogen Activator and its Expression inEscherichia coli,” Mol. Biol. Med. 3:279-292, Academic Press Inc. (1986).
Heussen, C. and E.B. Dowdle, “Electrophoretic Analysis of Plasminogen Activators in Polyacrylamide Gels Containing Sodium Dodecyl Sulfate and Copolymerized Substrates,”Anal. Biochem. 102:196-202, Academic Press, Inc. (1980).
Heussen, C. et al., “Purification of Human Tissue Plasminogen Activator with Erythrina Trysin Inhibitor,”J. Biol. Chem. 259:11635-11638, The American Society of Biological Chemists, Inc. (1984).
Hu, C.-K. et al., “Tissue-Type Plasminogen Activator Domain-Deletion Mutant BM 06.022: Modular Stability, Inhibitor Binding, and Activation Cleavage,”Biochemistry 33:11760-11766, American Chemical Society (1994).
Kipriyanov, S.M. et al., “High level production of soluble single chain antibodies in small-scaleEscherichia colicultures,”J. Immunol. Methods 200:69-77, Elsevier Science B.V. (1997).
Ko, J.H. et al., “High-level Expression and Secretion of Streptokinase inEscherichia coli,” Biotechnol. Lett. 17:1019-1024, Chapman & Hall (1995).
Kouzuma, Y. et al., “The Tissue-Type Plasminogen Activator Inhibitor ETIa fromErythrina variegata:Structural Basis for the Inhibitory Activity by Cloning, Expression, and Mutagenesis of the cDNA Encoding ETIa,”J. Biochem.(Tokyo)121:456-463, The Japanese Biochemical Society (1997).
Lasters, I. et al., “Enzymatic properties of phage-displayed fragments of human plasminogen,”Eur. J. Biochem. 244:946-952, Springer International on behalf of the Federation of European Biochemical Societies (1997).
Lobel, L.I. et al., “Filamentous Phage Displaying the Extracellular Domain of the hLH/CG Receptor Bind hCG Specifically,”Endocrinology 138:1232-1239, The Endocrine Society (1997).
Lubiniecki, A. et al., “Selected Strategies for Manufacture and Control of Recombinant Tissue Plasminogen Activator Prepared from Cell Cultures,” InAdvances In Animal Cell Biology and Technology for Bioprocesses,R.E. Spier et al., (ed.), Butterworth & Co., London, p. 4

Affiliated with

Also associated with

Rating

Method for large scale production of recombinant DNA-derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for large scale production of recombinant DNA-derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for large scale production of recombinant DNA-derived... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3477996